Respironics v60 ventilator

We undertook a multicenter retrospective analysis of patients admitted to one teaching hospital and three general hospitals in Japan. The study was approved by the institutional review board in each institution. We retrieved the medical records of all adult patients (≥18 years old) with an estimated P_aO₂/F_IO₂ (P/F) ratio of <300 who received HFNC (HFNC group) or NIV (NIV group) as first‐line respiratory support between January 2012 and December 2017. Patients were excluded if they had chronic respiratory failure without acute exacerbation, received home‐based NIV, their respiratory support was suspended for surgery or invasive procedures, or data were incomplete. There were no established protocols for the use of alternative respiratory support or intubation in any of the institutions; the choice of respiratory support was made by the attending physician. The NIV group included patients who received either non‐invasive continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BPAP). Dedicated NIV ventilators (BiPAP vision or Respironics V60 ventilator; Philips Respironics, Murrysville, PA, USA) and a full‐face mask were used for NIV. The Nasal High Flow system (Fisher & Paykel Healthcare, Auckland, New Zealand) was used for HFNC.

NIV was performed with Respironics V60 Ventilator (Philips Respironics: USA) in S/T mode, as recommended in our unit protocol: the pressure support was increased by 2 cmH₂O steps depending on the patient’s tolerance, up to a maximum of 20 cmH₂O to reach a tidal volume of 8 mL/kg of ideal body weight. The expiratory positive airway pressure was between 5 cmH₂O and 10 cmH₂O. The FiO₂ was adapted to reach an oxygen saturation of 90%–92%. The interface was a full-face mask (PerformaTrak, Philips Respironics).